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Background: Zoledronic acid (ZOL) is the most potent nitrogen-containing 
bisphosphonate (N-BPs) that strongly binds to bone mineral and acts as a 
powerful inhibitor of bone resorption, already clinically available for the 
treatment of patients with osteolytic metastases. Recent data also suggest that 
ZOL, used in breast cancer, may provide more than just supportive care 
modifying the course of the disease, though the possible molecular 
mechanism of action is still unclear. 
Aims: Since breast cancer is one of the primary tumors with high propensity 
to metastasize to the bone, we investigated, for the first time, differential gene 
expression profile on MCF-7 breast cancer cells treated with low doses of 
ZOL (10µM).  
Materials and Methods: Microarrays analysis was used to identify, describe 
and summarize evidences regarding the molecular basis of actions of ZOL 
and of their possible direct anti-tumor effects. 
We validated gene expression results of specific transcripts involved on 
major cellular process by Real Time and Western Blot analysis and we 
observed inhibition of proliferation and migration through MTT and Matrigel 
assay.  
Results: We then focused on changes in the cytoskeletal components as FN1, 
actin, and anti angiogenic compounds as TGF-β1 and THBS1. The up-
regulation of these products may have an important role in inhibiting 
proliferation, invasion and angiogenesis  mediated by ZOL. 
Conclusions: In conclusion, in the present studies, we investigated the role 
of ZOL in the regulation of breast cancer cell invasion. Our results 
demonstrated that ZOL, via cytoskeletal remodelling, plays an inhibitory role 
in breast cancer cell invasion, possibly by specifically up-regulating the TGF-




















Zoledronic Acid in Breast Cancer
 
 
Breast cancer is the most frequently diagnosed cancer in women around the 
world and bone is its most common 
ZOL is a potent nitrogen-containing bisphosphonate
inhibitor of bone resorption that reduce
and prevents treatment-induced bone loss
 
 




In oncology, its role in metastatic bone disease is well 
there is increasing interest in its
cancer-induced bone loss and its 
N-BP shave been shown to inhibit the mevalonate pathway involved in the 
synthesis of cholesterol, through inhibition of the enzyme farnesyl
diphosphate synthase (FPPS) (Figure 
production of the isoprenoid lipids farnesyl
geranyl diphosphate (GGPP) both






associated site of metastasis [1]. 
 (N-BPs) (Figure 1), 





established [3], but 
 potential role in preventing and treating 
possible anti-tumor effects [4]. 
 
2). This process leads to the decreased 
 diphosphate (FPP) and geranyl 









Small GTP-ases signalling regulates key cellular processes including 
proliferation, cell motility, angiogenesis, survival and migration, all 
mechanisms implicated in the development and spreading of many types of 
cancer including breast cancer [5-8].  
 
 
Zoledronic Acid and  angiogenesis 
 
 
Bisphosphonates, ZOL in particular,  induce also tumor cell apoptosis and 
stimulate γδ T cell cytotoxicity against tumor cells. In vivo, ZOL inhibit bone 
metastasis formation and reduce skeletal tumor burden in mouse models. 
This may reflect direct antitumor effects and indirect effects via inhibition of 
bone resorption. In addition, ZOL inhibits experimental angiogenesis in vitro 
and in vivo [9]. Data from in vitro and pilot studies suggest that ZOL reduces 
circulating levels of vascular endothelial growth factor (VEGF) in metastatic 
breast cancer patients [10,11], suggesting these drugs could interfere with 
tumor-associated angiogenesis. Evidence in vivo already exists that ZOL  
treatment inhibits tumor-associated angiogenesis by inducing a profound 
reduction in macrophages infiltrating mammary or cervical carcinoma 
lesions, associated with decreased VEGF and matrix metalloprotease-9 
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(MMP-9) levels in the tumor microenvironment [12]. Interactions of cells 
with their surroundings can have profound influences on gene expression and 
cellular behavior [13-15]. 
Angiogenesis and regulation of tumor environment is essential for cancer 
growth and progression, and therefore, anti-angiogenesis is one promising 
strategy to treat cancer [16]. As angiogenesis is essential for tumor growth 
and metastasis, controlling tumor-associated angiogenesis is a promising 
tactic in limiting cancer progression. The tumor microenvironment comprises 
numerous signaling molecules and pathways that influence the angiogenic 
response. Understanding how these components functionally interact as 
angiogenic stimuli or as repressors and how mechanisms of resistance arise is 














Numerous anti-angiogenic factors have been described as transforming 
growth factor β-1(TGF-β1) and relative TGF-β1 /SMAD (small mother 
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against decapentaplegic) signaling pathway plays an important role in cancer 
cells and leads to growth inhibition, differentiation and apoptosis [17]. The 
TGF-βs represent a family of multifunctional cytokines that modulate the 
growth and function of many cells, including those with malignant 
transformation. Their signaling pathway are frequently involved in 













Recent data  suggest that activation of the TGF-β pathway leads to the 
induction of apoptosis closely followed by the induction of cytostasis, 
resulting in different carcinoma regression [19,20]. An important natural 
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activator of TGF-β1 is Thrombospondin 1 (THBS1), a trimeric glycoprotein 
strongly bound to the extracellular matrix (ECM) [21] and a potent natural 















Thrombospondins have been termed adhesion-modulating or matricellular 
components of the extracellular matrix. Its ability to block migration of 
endothelial and cancer cells in vitro has been shown to be independent of the 
activation of TGF-β1 [23,24]. THBS1 affects ECM structure and function 
both through direct interactions and indirect effects on other components that 
are secreted by the cell [25]. Consider that cell adhesion to ECM is crucial to 
several steps in tumor progression and metastasis, many studies have 
demonstrated that THBS1 mediates cellular adhesion of numerous cell types 
and several transformed cell lines [24,26]. Inhibition of angiogenesis is also a 
consequence, in part, of reorganization of the actin cytoskeleton and 
disassembly of focal adhesions in endothelial cells and to inhibits cellular 













The molecular and physical composition of the extracellular matrix (ECM) 
can be affected by tumor cells themselves, as well as multiple stromal cell 
types. Alterations in the expression of ECM-related genes have been 
identified in gene expression signatures related to poor prognosis and 
metastases in breast cancers. Indeed, changes in the cytoskeletal components 
such as production and organization of fibronectin (FN1), actin and collagen 




Zoledronic Acid and MicroRNA expression 
 
Currently there is no evidence on the possible alteration of the expression of 
miRNAs in response to pharmacological treatment with ZOL, but it would be 
interesting and innovative to hypothesize the molecular mechanisms that 
allow their use in synergistic anticancer therapies. MicroRNAs are small non-
coding RNAs that regulate the expression of different genes, including genes 
involved in cancer progression, angiogenesis and metastasis. 
MicroRNAs (miRNAs) are small, endogenous noncoding RNAs, 21 to 24 
nucleotides (nt) long, which induce posttranscriptional gene silencing, 
recognizing their target mRNAs by base complementarity. MiRNA genes are 
encoded in introns or exons of a protein-coding gene or in the intergenic 
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regions, and it has been esti- mated that they regulate up to 30% of human 
genes. miRNAs are key regulatory molecules involved in regulation of a 
wide variety of fundamental cellular processes, such as proliferation, death, 
differentiation, motility and invasiveness. Aberrant expression of miRNAs 
has been observed in a diversity of pathological events. Importantly, 
deregulation or genetic changes of miRNAs have been critically implicated in 
the pathogenesis of most human cancer. The knowledge of mechanisms 
underlying the role of miRNAs in cancer initiation and progression provided 
a tool to create different strategies for using miRNAs as potential targets for 
cancer treatment. 
Since experimental evidence shows that miRNAs may represent valid 
diagnostic and prognostic markers in human cancer, is intuitive to analyze  
that the aberrant expression of miRNAs in different tumor types is related to 

















Zoledronic acid (ZOL) is the most potent nitrogen-containing bisphosphonate 
(N-BPs) that strongly binds to bone mineral and acts as a powerful inhibitor 
of bone resorption, already clinically available for the treatment of patients 
with osteolytic metastases. Recent data also suggest that ZOL, used in breast 
cancer, may provide more than just supportive care modifying the course of 
the disease, though the possible molecular mechanism of action is still 
unclear. 
Since breast cancer is one of the primary tumors with high propensity to 
metastasize to the bone, we investigated, for the first time, differential gene 
expression profile on MCF-7 breast cancer cells treated with low doses of 
ZOL (10µM). Microarrays analysis, and miRNA expression profile, was used 
to identify, describe and summarize evidences regarding the molecular basis 
of actions of ZOL and of their possible direct anti-tumor effects. 
We validated gene expression results of specific transcripts involved on 
major cellular process by Real Time and Western Blot analysis and we 
observed inhibition of proliferation and migration through MTT and Matrigel 
assay. We then focused on changes in the cytoskeletal components as FN1, 
actin, and anti angiogenic compounds as TGF-β1 and THBS1. The up-
regulation of these products may have an important role in inhibiting 












            








Cell culture  
Human breast cancer cell lines, MCF-7, purchased from the American Type 
Culture Collection (Rockville, MD, USA) were grown in Dulbecco’s 
modified Eagle’s medium Gibco DMEM:F12 (Invitrogen, Carlsbad, CA) 
containing 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin 
(P/S) (Gibco). Cells were incubated at 37°C in a humidified atmosphere of 
5% of CO2. Eighty % confluent cultures were stimulated with either 10µM of 
zoledronate (ZOL) for 24, 48 and 72h. ZOL was kindly provided by Novartis 
Pharma AG. The stock solution of ZOL was prepared at a concentration of 4 
mg/ml in distilled water, and aliquots were stored at -20°C. 
 
Cell growth assays 
Seventy percent confluent cultures were treated with 10, 50 and 100 µM of 
ZOL. Cell numbers before and after 1, 2  and 3 days of treatment were 
determined by counting the cells. All assays were done in triplicate and 
repeated at least twice.  
 
Cell viability assay 
Cell viability in human breast cancer cell lines, MCF-7, treated with 10, 50 
and 100 µM of ZOL for 24h, was determined by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as previously described in 
literature [34] with minor modifications. Briefly, MCF7 cells were seeded in 
flat-bottomed 96-well plates at a density of 10000 cells/well. Twenty-four 
hours later, growing cells were washed and treated for 24 hour with the ZOL 
(10 and 100uM). Cell viability  was measured using MTT at a concentration 
of 0.5 mg/ml (20 µl/well). After 1 hour incubation at 37 °C cells were 
solubilized in DMF (Dimethyl formamide) solution (DMF/H2O, 1:1, pH 4.7) 
containing 20%SDS for an additional incubation time of 16 hours at 37 °C to 
dissolve the blue formazan product. Optical density was measured at 570 nm 
using a 96-well plate reader (EL800 Biotek Instruments). All of the 
experiments were run in sextuplicate and repeated twice. 
 
Microarray Analysis 
Total cellular RNA was isolated from MCF-7 cells treated with ZOL (10 µM) 
for 24h using the miRNeasy Mini Kit (Qiagen Inc, Valencia, CA) and 
quantified through 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA). 5 µg of total RNA was reverse transcribed using the high capacity 
cDNA archive kit (Applied Biosystems) according to vendor's instructions. 
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Then cDNAs were in vitro transcribed for 16 hours at 37°C by using the IVT 
Labelling Kit (Affymetrix) to produce biotinylated cRNA. Labelled cRNA 
was isolated by using the RNeasy Mini Kit column (QIAGEN). Purified 
cRNA was fragmented to 200-300 mer using a fragmentation buffer. The 
quality of total RNA, cDNA synthesis, cRNA amplification and cRNA 
fragmentation was monitored by capillary electrophoresis (Bioanalizer 
2100,Agilent Technologies). Fifteen micrograms of fragmented cRNA was 
hybridised for 16 hours at 45°C with constant rotation, using a human 
oligonucleotide array U133 Plus 2.0 (Genechip, Affymetrix, Santa Clara, 
CA). After hybridisation, chips were processed using the Affymetrix Gene 
Chip Fluidic Station 450 (protocolEukGE-WS2v5_450). Staining was made 
with streptavidin- conjugated phycoerythrin (SAPE)(Molecular Probes), 
followed by amplification with abiotinylated anti-streptavidin antibody 
(Vector Laboratories), and bya second round of SAPE. Chips were scanned 
using a Gene Chip Scanner 3000 G7 (Affymetrix) enabled for High-
Resolution Scanning. Images were extracted with the Gene- Chip Operating 
Software (Affymetrix GCOS v1.4). Quality control of microarray chips was 
performed using the AffyQCReport software [35]. A comparable quality 
between microarrays was demanded for all microarrays within each 
experiment. 
 
Microarray Statistical Analysis 
The background subtraction and normalization of probe set intensities was 
performed using the method of Robust Multi array Analysis (RMA) 
described by Irizarry et al. [36]. To identify differentially expressed genes, 
gene expression intensity was compared using a moderated test and a Bayes 
smoothing approach developed for a low number of replicates [37]. To 
correct for the effect of multiple testing, the false discovery rate, was 
estimated from p-values derived from the moderated t test statistics [38]. The 
analysis was performed using the affylmGUI Graphical User Interface for the 
limma microarray package [39]. 
 
Matrigel Invasion Assay 
The invasive potential of breast cancer cells was assessed in vitro in matrigel-
coated invasion Chambers (BD BioCoat Matrigel Invasion Chamber; Becton 
Dickinson Biosciences, Franklin Lakes, NJ, USA) in accordance with the 
manufacturer's instructions. Cell invasion experiments were performed using 
a 24-well companion plate with cell culture inserts containing 8 um pore size 
filters. Untreated MCF-7 cells and drug-treated MCF-7 cells with ZOL 10 
µM for 24 and 48h (5 x 104/500 ul) were added to each insert (upper 
chamber), and the chemoattractant (FBS) was placed in each well of a 24-
well companion plate (lower chamber). After a 22h incubation at 37°C in a 
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5% CO2 incubator, the upper surface of the filter was wiped with a cotton-
tipped applicator to remove non invading cells. Cells that had migrated 
through the filter pores and attached on the under surface of the filter were 
fixed and stained by Diff-Quik staining kit (BD, Becton Dickinson 
Biosciences). The membranes were mounted on glass slides, and the cells 
from random microscopic fields (x40 magnification) were counted. Five 
fields per membrane were randomly selected and counted in each group. All 
experiments were run in duplicate, and the percentage of invasive cells was 
calculated as the percentage invasion through the matrigel membrane relative 
to the migration through the control membrane, as described in the 
manufacturer's instructions. 
 
Real time-quantitative PCR (Q-PCR) 
Total cellular RNA was isolated from MCF-7 cells treated with ZOL (10 µM) 
for 24h using the miRNeasy Mini Kit (Qiagen Inc, Valencia, CA) and 
quantified through 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA). 5 µg of total RNA was reverse transcribed using the high capacity 
cDNA archive kit (Applied Biosystems) according to vendor's instructions. 5 
µl of the RT products were used to amplify Fibronectin (FN1) 
(hs01549976_m1), ACTIN (hs99999903_m1), TGF-β1 (hs00998133) and 
Trombospondin 1 (THBS1) (hs00962914) sequences using the TaqMan gene 
expression assay (Applied Biosystems). To normalize quantitative real-time 
PCR reactions, parallel TaqMan human Cyclophilin (4326316E) control 
reagents assays (Applied Biosystems) were run on each sample. Changes in 
the target mRNA content relative to control mRNA were determined using a 
comparative Ct method to calculate changes in Ct, and ultimately fold and 
percent change. An average CT value for each RNA was obtained for 
triplicate reactions. 
 
Western blotting (WB)  
The cells were treated with 10 uM ZOL for 24, 48, 72 , and also 96 h or left 
untreated, and then were lysed to obtain total proteins using complete Lysis-
M reagent (Roche, Mannheim, Germany)Protein concentration was 
determined by the Bradford method and the expression of proteins was 
analyzed in 150 ug of total protein lysates. Proteins were separated on  a gel 
with 8 and 10% polyacrylamide under denaturing conditions and transferred 
by electrophoresis to a nitrocellulose membrane. Nonspecific binding was 
blocked by soaking membranes in 1× TBS, 5% powdered milk, and 0.05% 
Tween-20 for at least 60 minutes at room temperature. Membranes were 
incubated with the following primary antibodies: p44/42 MAPK (Erk1/2) 
mouse mAb# 9107  (at 1:2000), Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (197G2) Rabbit mAb #4377 (at 1:2000), Akt1 (2H10) 
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Mouse mAb #2967 (at 1:100) and Phospho-Akt (Ser473) (193H12) Rabbit 
mAb #4058 (at 1:1000) were from Cell Signaling Technology, Fibronectin 
antibody, Rabbit polyclonal antibody to FN1 GTX112794 (at 1:1000), beta 
Actin [AC-15] antibody, mouse monoclonal GTX26276 (at 1:5000) and TGF 
beta [TB21] antibody, mouse monoclonal GTX21279 (at 1:1000) were from 
Gene Tex, Inc., Smad4 (MAB1132 at 1 µg/mL) and anti-Smad2/3 (#07-408 
at 1:500) were from Millipore Corporation, THBS1 mouse monoclonal and 
GAPDH (6C5): sc-32233 were from Santa Cruz Biotechnology. After the 
membranes were washed three times with TBS plus 0.05% Tween-20 for 30 
minutes, they were incubated with the following peroxidase (HRP)-
conjugated secondary: anti-rabbit, anti-mouse and anti-goat antibody (2030; 
Santa Cruz Biotechnology) diluted to 1:1000, followed by three washes with 
TBS plus 0.05% Tween-20. Detection was performed with 
chemiluminescence detection reagents (ECL; Pierce Biotechnology Inc., 
Rockford, IL). 
 
miRNAs Expression Profiling Using the TaqMan Human MicroRNA 
Array 
Total cellular RNA and miRNAs were isolated from MCF7 cells using the 
miRNeasy Mini Kit (Qiagen Inc, Valencia, CA, USA) and quantified through 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 600 ng of 
total RNA was reverse transcribed using Megaplex™ RT Primers Human 
Pool A (Applied Biosystems, Foster City, CA, USA) according to 
manufacturer’s instructions. Conditions for the reverse transcription reaction 
were as follows: 16°C for 2 minutes, 42°C for 1 minute, 50°C for 1 second 
for 40 cycles, 85°C for 5 minutes then hold at 4°C. Obtained cDNA was 
diluted, mixed with TaqMan Gene Expression Master Mix, and loaded into 
each of the eight fill ports on the TaqMan® Human MicroRNA Array A 
(Applied Biosystems, Foster City, CA, USA). The Taq-Man Human 
MicroRNA Array is a 384-well microfluidics card containing 365 primer-
probe sets for individual miRs as well as duplicates of 3 primer-probe sets for 
endogenous small nucleolar RNAs and duplicate negative control blank 
wells. The array was centrifuged at 1,200 rpm twice for 1 minute each, and 
then run on ABI-PRISM 7900 HT Sequence Detection System (Applied 
Biosystems) and the data were quantified using the SDS 2.1 software and 
normalized using the MammU6 as endogenous control. The cycle threshold 
(Ct) value, which was calculated relatively to the endogenous control, was 
used for our analysis (Ct). The 2-CT (delta-delta-Ct algorithm) method 
was used to calculate the relative changes in gene expression. 
 
Predictive miRNAs for Predictive Target Genes  
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To determine miRNA targets we employed 5 integrated databases: 
TargetScan 5.1, MiRanda, PICTAR, miRbase and DIANA-microT databases. 
These databases search the presence of conserved 8mer and 7mer sites on the 
3’UTR parts of messenger RNA that match the seed region of each miRNA. 

















 ZOL inhibit Breast Carcinoma Cells proliferation.
 
In order to identify the lower dose of ZOL
proliferative effect on MCF-
concentrations (10-100 µM ) of ZOL
Cell count showed that cell growth
concentrations used (Figure 1). In particular,  tumor cell growth was reduced 
of about 40%  at a ZOL concentration of 100 
of 24 h while the lower ZOL concentration
(20%), but effective. Consider that
were not shown a significant difference, we can assert that
lower concentration for only 24 h is sufficient
proliferation, also confirmed by
active cells by  MTT assay (Figure 
 
Figure 1. A-B ZOL inhibits cell growth in vitro. About 10
and 96-well tissue culture plates and exposed to ZOL at a concentration ranging from 10 to 





 sufficient to induce an anti 
7 cell proliferation we tested different 
 for 24, 48 or 72 hours (h). 
 was inhibited by ZOL versus control at all 
µM over a period of incubation 
 (10 µM) was slightly less efficient 
 inhibition rates of 10 and 100 µM of ZOL 
 the treatment at 
 to induce a inhibition of 
 determination of number  of metabolically 
1 A, B).   
 
5
 and 104  cells were cultured in 6-well 
(A) and MTT assay 
 On the basis of these data, we have selected this concentration of ZOL for all 
the subsequent experiments. 
To elucidate the mechanisms by which cell proliferation is suppressed, we 
have analyzed the effects of ZOL on  specific proli
course experiments were performed using Western blot 
phosphorylation and thus activation
that phosphorilation of MAPK and AKT was decreased significantly after 
both 24 h and 48 h exposure to 10 µ
Thus, as expected and previously reported 
doses of ZOL induced decrease of both MAPK and Akt
ZOL inhibits the  cell proliferation and the ability of tumor cells to expand 
once they colonize bone [41-44].
 
 
Figure2. Effects of ZOL addition on MAPK and Akt
were treated with 10 µM ZOL for 24, 48, 72 and 96 h. Thereafter, both the expre
activity of MAPK p44/42 and AKT were evaluated.
Determination of the expression and phosphorylation of MAPK p44/42 and AKT evaluated as 
described in ‘‘Material and Methods’’. Expression of the house







 of MAPK and AKT pathways. We found 
M ZOL (Figure 2). 
with higher doses [40], also low 
 activity, by which 
 
 
-dependent pathways on MCF-7 cells. Cells 
ssion and 
 
-keeping protein GAPDH, used 
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Gene expression profile of MCF-7 breast cancer cells treated with low 
doses of Zoledronic Acid 
 
The main aim of this study was to investigate the molecular mechanisms by 
which low doses of ZOL exert their antitumor effects in breast cancer cells. 
Though ZOL have clearly demonstrated to inhibit proliferation and induce 
apoptosis in cancer cell lines by interfering with the mevalonate pathway [5-
8], the type and pattern of downstream genes modulated by ZOL treatment 
are still unknown.  
In order to investigate molecular basis of anti-tumoral effect of low doses of 
ZOL on breast cancer cells, we have evaluated the expression profiling of 
MCF-7 treated with 10 µM of ZOL for 24 h versus untreated, using a cDNA 
microarray platform Affymetrix. Of the 33,000 independent features on the 
microarrays, 126 were found to be differentially expressed after 24 h of 
treatment. In particular, 17 genes were downregulated (−1.57 to −2.88), and 
109 genes were upregulated (+1.52 a +5.27). We considered for following 
analysis only the genes with fold change >2 as significative upregulation or 
downregulation and with statistical difference of expression of each gene was 
at least p< 0.001 (Figure 3 A).  
We grouped genes related to biological process, molecular function 
categories and finally in cellular component categories, that have changed in 
a statistically significant manner (p-value ≤ 0.05) after treatment with ZOL 
(Figure 3 B, C, D). The most significant changes in biological processes 
confirmed the involvement of  ZOL in metabolic processes, in fact 38 genes 
are differentially regulated. Other changes were observed in the cellular 
localization (24 genes regulates), cell communication (20 genes regulated) 
and in cell proliferation pathways (8 genes) (Figure 3B). 
Analysis also showed a regulation of molecular function categories, as 
protein (37 genes) and ion binding (27 genes), and transporter activity (11 
genes) affected by ZOL (Figure 3C).  Cellular component categories that 
result differentially regulated by gene expression profile comprend 
membrane and cytoskeletal  components (48 genes), nucleus (19 genes) and 
endoplasmic reticulum components (13 genes) (Figure 3D). 
Alterations in gene expression identified by microarray analysis show 
modification of possibles early-response genes as the treatment with ZOL 
was carried out  for only 24h and were further investigated by real-time 






Figure 3. A. Treatment with ZOL globally affects gene expression profile in MCF-7 cells. 
B, C, D. Corrected microarray signal values of genes involved in different biological process, 
clustered by specific functions (Biological process, Cellular function, Cellular component) of 
MCF-7 cells treated for 24 hours with 10 µM ZOL in comparison to control cells. 
 
 
Effects of ZOL on Breast Carcinoma Cells Invasion 
 
In light of previous observation, we hypothesized that the inhibitory effect of 
ZOL on cellular growth and deregulation of cytoskeletal component observed 
by analysis of gene expression, could result in inhibition of tumor cell 
invasion. To address this question, alterations in gene expression, identified 
by microarray analysis, were further investigated by real-time quantitative 
reverse transcription-PCR and Western blot analysis to investigate whether 
alterations in gene expression were translated into corresponding changes in 
protein levels.  
We found that treatment with ZOL induces transcription and protein 
expression of some matrix and cytoskeletal components, such as Fibronectin 
and actin, involved in cancer microenvironment. In particular, the up-
regulation of gene coding for FN1 shown by microarray (fold change of 1.93) 
was confirmed by Real Time RT-PCR with a fold change of 2.3 compare to 
control (Figure 4A) and mRNA expression of actin, analyzed by Real time 
RT-PCR, showed a fold change of 1.5. Interestingly, a high protein 
expression is maintained even at longer treatment (at 96 h) and with the most 
activating effect in the protein products, indicating the potential 
consequences of ZOL treatment on the morphology and cell motility, 
considered the cellular roles of FN1 and actin as factors that can change the 
ECM (Figure 4B). 
 
  
Figure 4. Effect of ZOL on the mRNA expression and protein levels of FN1 and ACTIN. A. 
Effect of ZOL 10µM on the mRNA expression of FN1 and ACTIN, as quantified by real time 
PCR in MCF-7 cells. B. Effect of ZOL on FN1 and ACTIN protein levels. MCF
incubated with low concentration of ZOL for different times, and protein expression were 
examined by Western blot developing with the enhanced chemoluminescence reagent (ECL). 
Each membrane was also probed with GAPDH to confirm equal loading.
 
 
Then, the effects of ZOL, on the 
investigated by Matrigel assays. We observed that
only 10 µM of the drug, resulted in a reduction in invasion in a time 
dependent manner, reaching 60–
These results demonstrate that ZOL treatment has a strong inhibitory effect 
not only on MCF-7 cells growth but also on 
the alteration of FN1 and actin expression, could be involved in invasion of 
human breast cancer cell lines.  
26 
 
-7 cells were 
 
in vitro invasion of MCF-7 were 
 cells treated even with 
90% inhibition after 24 h (Figure 5).  





Figure 5. ZOL  decrease the invasive potential of human breast cancer cells
the invasion of MCF-7 cells. Treated or not 
invasion chambers as described in ‘‘Material and Methods’’, and the cell invasion was evaluated. 
The invaded cells for each insert were stained and quantified. The results are expressed as a 
percentage of MCF-7 not treated cells (B). The experiments were performed at least 
times, and the results were always similar. 
 
 
ZOL increases expression of anti 
carcinoma cell lines. 
 
ZOL can inhibit angiogenesis of tumor cells
that the use of this agent may impede the development of bone metastases
[45,46]. 
THBS1, TGF-β1 and its signaling effector
cell biology, such as growth arrest and 
important for the metastatic dissemination of tumo
location to lymph or blood vessels 
In order to investigate the effects on 
ZOL, we observed specific mRNA expression and protein levels of 
β1and THBS1, to confirm over expression 
27 
 
. Effect of ZOL on 
with ZOL 10 µM for 24 h, were plated onto Matrigel 
3 different 
Data are represented as percentage of control (100%). 
angiogenetic factors in Breast 
 and emerging evidence suggests 
 
s regulate many aspects of tumor 
cell motility, the latter of which is 
r cells from their primary 
[47-49]. 
angiogenesis induced by low dose of 
TGF-
observed by microarrays analysis, 
 in particular, TGF-β1showed a fold change of +2.3 and 
of +2,6 compare to untreated control.
After only 24 h exposed to ZOL
was significantly increased (Fig
these two protein in anti angiogenetic
ZOL. 
 
Figure 6. Effect of ZOL on the transcript and protein levels of THBS1 and 
expression of THBS1 and TGFβ1, as quantified by real time PCR in MCF
Effect of ZOL on THBS1 and TGFβ1 
concentration of ZOL for different times, and protein expression were examined by Western 
blot. The house-keeping protein GAPDH was used as loading control. The experiments were 




Moreover, since classic TGF-β signaling involves the activation of 
and Smad4, direct mediators that
Smad expression using Western blot method. 
28 
THBS1 a fold change 
 
, both transcription and protein expression 
ure 6), indicating possible implication of 
 process mediated by low doses of 
 
TGFβ1. A. mRNA 
-7 cells treated. B. 
protein levels. MCF-7 cells were incubated with low 
ar. 
Smad2/3 
 accumulate into the nucleus, we examined 
Smad complexes interact with 
 transcription factors, co-activators, and co
in the regulation of different target gene expression 
Treated MCF-7 cells exhibited a substantial increase in Smad 2/3 at 24 h 
while Smad4 peaked at 24 h an
indicating that MCF-7 cells possibly contain sufficient quantities of receptors 





Figure 7.  Effects of ZOL on TGF-β1-dependent pathway and Smad
were treated with 10 µM ZOL for 24, 48, 72 and 96 h. Determination of the expression 
SMAD2/3 and SMAD4 evaluated after blotting with specific antibodies, as described in 
‘‘Material and Methods’’. Expression of the house
control. The experiments were performed at least 3 different times, and the results were always 
similar. 
 
Global microRNA expression profile in Breast Cancer Cells treated with 
ZOL 
 
To investigate direct anti-tumor effect
miRNA expression profile in MCF
ZOL were analyzed. miRNAs are small non
expression of different genes, including genes involved in cancer 
progression, angiogenesis and metastasis.
After treatment with Zoledronic acid 10
miRNAs expression were analysed.
Statistical analysis showed 261 microRNAs differentially expressed in breast 
cells after treatment with zoledronate 10 
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-repressors where they participate 
[50]. 
d began to decrease after 72 h (Figure 7), 
- β 1 (Figure 7).  
 
 protein expression. Cells 
-keeping protein GAPDH, used as loading 
 of ZOL by MicroRNAs (miRNAs), the 
-7 breast cancer cell lines treated with 
-coding RNAs that regulate the 
 
µM in MCF7 breast cancer cells, 
 





 Figure 8. Heat Map. Graphical representation




In particular, induced 11 MicroRNA expression that were not expressed in 
breast cells untreated, 9 miRNAs significantly up
down-regulated (Figure 9). 
 Bio-informatic predictions indicate that in most part these miRNAs are 
involved in extracellular matrix structure, cell migration, cell adhesion, 
cytoskeletal organization, immune response and 
cascade. 
This result showed that zoledronic acid was found 
miRNA expression. In particular on cellular pathways implicated in cell 
proliferation, invasion, migration, and immune anti
organism. Based on these data, we pro
zoledronic acid to patients to treat cancer metastasis and also for its anti





Figure 9. Graphical representation of miRNAs
(B) and newly expressed miRNAs (C) 
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Because treatment with zoledronic acid at a concentration of 10 µ M induces 
an increase in protein expression of Fibronectin and β-actin compared to 
untreated MCF-7 cells, confirming the role of the drug in countering the 
motility and induce the adhesion of cells tumor. In light of these results, we 
sought to identify, from the list of miRNAs obtained, possible miRNAs that 
might be involved in this type of regulation. In this regard have been 
consulted on the network software, according to the criteria listed above, to 
identify predictors of target miRNAs. The research carried out seems to 
attach to the miR-96 and miR-525, down-regulated 83% and 70% 
respectively in the MCF-7 cells treated with zoledronic acid compared to 
control cells, a possible regulatory role in the expression of Fibronectin, date 
their inverse correlation of expression. Similarly, miR-223 and miR-377c, 
down-regulated by 65% and 81% respectively in the cell subjected to 
treatment with zoledronic acid compared to control cells, appear to have a 


















Preclinical studies have demonstrated that ZOL can inhibit proliferation, 
invasion, migration, and angiogenesis of tumor cells. Emerging evidence also 
suggests that the use of this agent may impede the development of bone 
metastases in mouse models [45,46]. The mechanism by which ZOL exerts 
its anti-cancer properties have already been investigated, and its direct effect 
on cancer cells, as well as the inhibitory effect on tumor angiogenesis, has 
been confirmed [51,52]. Several studies have demonstrated that, in vitro, the 
binding of breast and prostate cancer cells to bone surfaces is inhibited by 
ZOL, that this treatment also has an inhibitory effect on cell proliferation and 
that a decrease of cellular migration was observed when prostate and breast 
cancer cell lines were cultured with ZOL [4,53,54]. This mechanism seems to 
be mediated by the effects on the cytoskeleton through Rho A [5]. 
The main aim of our study was to investigate the molecular mechanisms by 
which ZOL exerts its antitumor effects in breast cancer cells by Microarray 
analysis. 
In order to identify the lower dose of ZOL sufficient to induce a moderate  
anti proliferative effect on MCF-7 cell proliferation we first performed cell 
proliferation assays, by cellular count and MTT. We tested different 
concentrations (10-100 µM ) of ZOL for 24, 48 or 72 h and we found that the 
highest inhibitive rate reached to nearly 50%.  
Considered that 10 µM of ZOL had shown a sufficient inhibitory effect, we 
have selected this concentration of ZOL for all the subsequent experiments. 
Data obtained from observation of the activation of major cellular pathways 
are indicative of mechanisms by which this drug is able to block cellular 
proliferation. In particular, we confirm, also with low doses, the inhibition of 
the phosphorylation state of AKT and MAPK protein [40], responsible for 
key cellular pathways.  
To deeply investigate the molecular mechanism by which ZOL acts as 
antitumor drug, we have performed a gene expression profiling of MCF-7 
breast cancer cells treated with low doses of ZOL, and we have demonstrated 
that ZOL induce differential expression of 126 genes with a strongly up-
regulation of different cytoskeletal and extracellular matrix component. 
Based on these results, we also hypothesized that low concentrations of ZOL 
may affect the processes of invasiveness in cancer cells by altering their 
ability to invade the tumor microenvironment and thus inhibit their metastatic 
potential. 
Because tumor cell invasion requires both cell migration and digestion of the 
basement membrane, we hypothesized that ZOL inhibited MCF-7 tumor cell 
invasion was mostly dependent on the cell surface activity driven by FN1 
expression and on remodeling of cytosckeletal components. Several studies 
suggest that FN1 is related to tumor invasion and metastasis [55,56] playing a 
key role in the tissue remodeling and cell migration events that occur during 
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normal development; it has been thought to have an important role in both 
tumor invasion and metastasis. In particular, FN1 is a major constituent of the 
cell surface of many cultured cells, and it is either eliminated or reduced on 
the surface of oncogenically transformed cells [55]. Many reports have 
suggested that there is a correlation between the loss of cell surface FN1 and 
the ability of a cell to metastasize [44].   
In our study, after treatment with10 µM of ZOL, FN1 and actin result up-
regulated both by Real Time RT-PCR and western blotting, indicating their 
possible involvement in cytoskeletal reorganization  induced by ZOL. 
On the basis of these considerations, we have  performed a Matrigel assay of 
MCF-7 breast cancer cells treated with ZOL at 10 µM for 24h, and we have 
demonstrated that ZOL strongly inhibits invasion of these cells. These data 
agreed with some earlier research in vitro [18,56]. 
However, the regulatory mechanism of FN1 expression of breast carcinoma 
is not clear.  It is thought it could be regulated by a variety of growth factors 
such as TGF-β1 frequently involved in suppressing the growth of human 
tumors [18].  
Infact our analysis confirmed that ZOL treatment have induced an up-
regulation of transcription  and of protein product of TGF-β1, letting us to 
speculate its involvement in transcriptional control of FN1. Since, classic 
TGF-β signaling involves the activation of Smad2/3 and Smad4, we also 
demonstrated that ZOL induce at 24 h an increase of  Smad2/3 and Smad4  as 
direct mediators of TGF-β signaling in final activation of anti angiogenetic 
effects of ZOL. 
ZOL can also inhibit angiogenesis of tumor cells and emerging evidence 
suggests that the use of this agent may impede the development of bone 
metastases [45,46]. 
We also found that low dose of ZOL, increased expression of THBS1, a 
factor involved in the angiogenesis process [55,56], but also in the regulation 
of FN1 and actin. THBS1, TGF-β1 and its signaling effectors regulate many 
aspects of tumor cell biology, such as growth arrest and cell motility, the 
latter of which is important for the metastatic dissemination of tumor cells 
from their primary location to lymph or blood vessels [47,48]. 
Moreover, in the profiles of miRNA expression in MCF-7 cells treated with 
low doses of zoledronic acid and compared with cells belonging to the same 
cell line but not subjected to drug treatment has been found that: the down-
regulation of miR-96 and miR-525 may be related in the regulation of 
fibronectin, the down-regulation of miR-223 and miR-337c could be 
determinant of the up-regulation of β-actin. These results suggest, therefore, 
emphasize the negative role that zoledronic acid has on cell motility and 
potential carcinogenic cell. Although these data are experimental, and even if 
zoledronic acid is a drug still being tested, these data indicate the future role 
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that ZOL could play as a cancer drug. Furthermore, the data obtained from 
the study of the expression profiles allow us to identify miRNAs that could 
serve as tumor markers of drug response. 
Finally, our results suggested that ZOL showed anti-proliferative and anti-
invasive effects in MCF-7 cells and that these data may depend on the 
activator effect of ZOL in the expression of extracellular matrix, cytoskeletal 
component, and anti-angiogenc factors found in this study.  On the basis of 
this preliminary results in vitro, it could be interesting to develop molecular 
therapeutic strategies based on the specific activation of the expression of 
particular component for inhibit tumoral growth and angiogenesis, or to 
evaluate in particular specific roles of FN1 and actin, blocking their 
expression, in inducing effect antiproliferative and anti-invasive of ZOL in 











This study strongly encourage the new experimental design for treatment of 
breast cancer based on administration of ZOL and to discover their target 
molecular in cancer cells for future more effective synergistic treatments. 
In conclusion, in the present studies, we investigated the role of ZOL in the 
regulation of breast cancer cell invasion. Our results demonstrated that ZOL, 
via cytoskeletal remodelling, plays an inhibitory role in breast cancer cell 
invasion, possibly by specifically up-regulating the TGF-β1/Smad signaling 
pathway, and the downstream activity of FN1 and ACTIN. 
On the basis of this results future work  have been hypothesized , it could be 
interesting to develop molecular therapeutic strategies based on the specific 
regulation of expression and/or function of cytoskeletal components and 
possibly miRNA associations treatments. 
Therefore, as subject of the next experiments, will be evaluated the activity of 
ectopic regulation of FN1 mRNA expression to study effective potential 
antiproliferative and anti-invasive of ZOL in human breast cancer cells, 
focusing more attention on the other factors or protein families that influence 
invasive potential of MCF-7 tumor cells in particular. 
Finally, these data strongly encourage the design of clinical trials based on 
the concomitant administration of ZOL and ectopic additional expression of 
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